Arazasetron - Sensorion
Alternative Names: R-azasetron besylate; R-azasetron besylate - Sensorion; SENS 401Latest Information Update: 01 Oct 2026
At a glance
- Originator Sensorion
- Class Ear disorder therapies; Heterocyclic bicyclo compounds; Oxazines; Small molecules
- Mechanism of Action Calcineurin inhibitors; Serotonin 3 receptor antagonists
-
Orphan Drug Status
Yes - Sensorineural hearing loss; Hearing loss
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Phase II/III Sensorineural hearing loss
- Phase II Hearing loss
Most Recent Events
- 23 Sep 2026 Arazasetron - Sensorion is available for licensing as of 01 Oct 2026. https://www.sensorion.com/en/
- 11 Jun 2025 Sensorion completes a phase II trial in Hearing loss (prevention) in France (PO) (NCT05628233)
- 10 Mar 2025 Sensorion completes enrolment in a phase IIa NOTOXIS trial for Hearing loss (Prevention) in France (NCT05628233)